https://www.thebodypro.com/category/maraviroc-selzentry-celsentri

Maraviroc (Selzentry, Celsentri)

The Latest

The Genetic Mutation Behind the Only Apparent Cure for HIV Img
News

The Genetic Mutation Behind the Only Apparent Cure for HIV

The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?

Selzentry Approved for Pediatric Use Img
News

Selzentry Approved for Pediatric Use

The U.S. Food and Drug Administration has approved Selzentry (maraviroc) 20 mg/mL oral solution, Selzentry (maraviroc) 25 mg and 75 mg tablets and updated the label to include use in pediatric patients 2 years of age and older weighing at least 10 kg...

Maraviroc Fails to Block SIV Infection in Orally Exposed Infant Macaques Img
Conference Coverage

Maraviroc Fails to Block SIV Infection in Orally Exposed Infant Macaques

Twice-daily oral maraviroc (Selzentry, Celsentri) failed to prevent SIV infection in infant macaques orally exposed to the virus, but the findings do not rule out potential use in human infants.

Oral Maraviroc PrEP Protects U.S. Women From HIV in 48-Week Study Img
Conference Coverage

Oral Maraviroc PrEP Protects U.S. Women From HIV in 48-Week Study

No woman taking daily maraviroc pre-exposure prophylaxis (PrEP) with or without tenofovir (TDF, Viread) or emtricitabine (FTC, Emtriva) became infected with HIV through 48 weeks in a randomized, double-blind, 188-woman U.S. study.

Future of Maraviroc as HIV PrEP Seems Likely to Be in Dual Combinations Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Future of Maraviroc as HIV PrEP Seems Likely to Be in Dual Combinations

Although the CCR5 inhibitor maraviroc is largely underused as an antiretroviral drug, several studies looking at whether it has a role as PrEP seem to support use in combinations.

Maraviroc + Raltegravir: Caution Needed Img
Lipodystrophy/Body Fat

Maraviroc + Raltegravir: Caution Needed

Researchers in France conducted an exploratory study with 44 HIV-positive participants. Their average age was 55 years and they had been taking ART for 15 years. For the five years prior to the study, their viral loads were less than 50 copies/ml.

A...

Promo Image
News

Conference Update From IAS 2011: Medication News

Among the usual conference suspects were drugs, drugs, and drugs! Here are some of the findings on how HIV drugs compare to one another:

Experimental Elvitegravir Stacks Up Against Isentress

In an advanced Phase 3 study, elvitegravir was found to b...

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings Img
News

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings

Here's a quick sampling of some of the more noteworthy HIV-related posters presented at a major research conference last week. Topics covered include a surprisingly high frequency of people quitting Atripla due to side effects; the decline of multidr...

Promo Image
Children (Ages 0-17)

Paediatric Antiretroviral Pipeline: Update on Etravirine and Maraviroc

Data were presented at the paediatric workshop and IAS 2011describing recent developments in the paediatric pipeline.

Etravirine

Thomas Kakuda from Tibotec showed pharmacokinetic (PK) data of the NNRTI etravirine (ETV) in treatment experienced chil...

Promo Image
News

Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir

HIV-positive people taking standard-dose atazanavir/ritonavir plus 150 mg of maraviroc once-daily had lower maraviroc maximum concentrations (Cmax) and average concentrations (Cavg) than HIV-negative people taking 300 mg of maraviroc twice daily with...